Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wuwei Yixin Granules is a Traditional Chinese Medicine (TCM) candidate developed by Jiangsu Kanion Pharmaceutical Co., Ltd. for the treatment of stable angina pectoris and coronary heart disease. The formulation is specifically designed to address the TCM syndrome of Qi and Yin deficiency combined with phlegm and blood stasis, which are common pathological states in cardiovascular conditions. The drug aims to alleviate symptoms of myocardial ischemia, improve cardiac function, and reduce chest pain through a multi-target approach characteristic of herbal formulations. As of early 2025, it is undergoing Phase 2 clinical evaluation in China to assess its efficacy and safety in this patient population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wuwei Yixin Granules.